Accolade (NASDAQ:ACCD) Issues Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Accolade (NASDAQ:ACCDGet Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.14, Briefing.com reports. Accolade had a negative return on equity of 20.30% and a negative net margin of 20.62%. The company had revenue of $106.40 million for the quarter, compared to analysts’ expectations of $104.87 million. During the same period in the previous year, the firm earned ($0.43) EPS. The firm’s revenue was up 9.8% compared to the same quarter last year. Accolade updated its FY 2025 guidance to EPS and its Q3 2025 guidance to EPS.

Accolade Price Performance

Shares of ACCD stock opened at $3.90 on Thursday. The stock has a 50 day moving average price of $4.02 and a 200 day moving average price of $5.80. Accolade has a 52-week low of $3.35 and a 52-week high of $15.36. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 2.80. The firm has a market capitalization of $312.03 million, a P/E ratio of -3.36 and a beta of 1.99.

Analysts Set New Price Targets

ACCD has been the topic of several research analyst reports. Guggenheim lowered their target price on shares of Accolade from $13.00 to $6.00 and set a “buy” rating on the stock in a report on Friday, June 28th. Stephens decreased their price target on shares of Accolade from $10.00 to $8.00 and set an “overweight” rating on the stock in a research note on Wednesday. Stifel Nicolaus lowered their target price on Accolade from $13.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, June 28th. Canaccord Genuity Group reduced their target price on shares of Accolade from $13.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Truist Financial decreased their target price on shares of Accolade from $9.00 to $7.50 and set a “buy” rating on the stock in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.38.

Get Our Latest Stock Analysis on ACCD

About Accolade

(Get Free Report)

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.

Featured Articles

Earnings History for Accolade (NASDAQ:ACCD)

Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.com's FREE daily email newsletter.